Join the BioNap Email List!

Monday, July 6, 2015

A Deep Look At Depomed's Billion-Dollar Bet On Nucynta

By Nisha Hirani, MD & Jason Napodano, CFA

For the purpose of this article, we would like to offer some background information on the burden of pain, and also draw attention to the recent acquisition of the NUCYNTA® (tapentadol) franchise by Depomed Inc. (DEPO). We continue to remain optimistic regarding the Depomed story, especially as it pertains to the NUCYNTA® franchise, as we strongly believe the transaction will be transformational for the company.

Please read the article on Seeking-Alpha: LINK

No comments:

Post a Comment